GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.
The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...
As GLP-1 adoption accelerates, food and beverage brands face structural shifts in consumption and strategic decisions on how to communicate them on pack.
The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.
New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...
New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.
Many Americans seeking popular weight-loss drugs like Wegovy and Zepbound turn to telehealth companies like Hims & Hers for cheaper, compounded alternatives. Those compounded drugs were only supposed ...
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or ...
The Kentucky Senate voted Wednesday to repeal that change, arguing it would cost the state too much to take on the cost of ...
Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results